Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Irene Ghobrial, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director, Clinical Investigator Research Program
  • Lavine Family Chair for Preventative Cancer Therapies
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Multiple myeloma
  • Waldenström’s Macroglobulinemia

Contact Information

  • Appointments617-632-3823 (new)
    617-632-4218 (follow-up)
  • Office Phone Number617-632-4218
  • Fax617-582-8608

Bio

Dr. Ghobrial received her MD in 1995 from Cairo University School of Medicine, Egypt. She completed her Internal Medicine training at Wayne State University, Mich., and her Hematology/Oncology subspecialty training at Mayo Clinic College of Medicine, Minn. She joined Dana-Farber in the field of Waldenstrom's macroglobulinemia and multiple myeloma in 2005. She is conducting research in the area of homing and migration of B cells and novel therapeutic agents in Waldenstrom's macroglbulinemia and multiple myeloma.

Board Certification:

  • Hematology, 2004
  • Internal Medicine, 2001
  • Medical Oncology, 2004

Fellowship:

  • Mayo Clinic, Graduate Medical Education, Hematology & Oncology

Residency:

  • Cairo University School of Medicine, Pediatrics
  • Sinai-Grace Hospital of Detroit, Internal Medicine

Medical School:

  • Cairo University School of Medicine

Research

ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discov. 2021 Jul; 2(4):338-353.
View in: PubMed

The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplant Cell Ther. 2021 Jun 06.
View in: PubMed

Inflammatory stromal cells in the myeloma microenvironment. Nat Immunol. 2021 06; 22(6):677-678.
View in: PubMed

Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021 Apr 29; 137(17):2360-2372.
View in: PubMed

Autonomous Calcium Signaling in Human and Zebrafish Podocytes Controls Kidney Filtration Barrier Morphogenesis. J Am Soc Nephrol. 2021 Apr 28.
View in: PubMed

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 Apr 08; 137(14):1905-1919.
View in: PubMed

Single-cell RNA sequencing: one step closer to the clinic. Nat Med. 2021 03; 27(3):375-376.
View in: PubMed

Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. 2020 12 10; 183(6):1714-1731.e10.
View in: PubMed

An In Vitro Differentiation Protocol for Human Embryonic Bipotential Gonad and Testis Cell Development. Stem Cell Reports. 2020 12 08; 15(6):1377-1391.
View in: PubMed

BELLINI: a renaissance for an era of precision therapy in multiple myeloma. Lancet Oncol. 2020 12; 21(12):1547-1549.
View in: PubMed

Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020 11; 98:106459.
View in: PubMed

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 Feb 20; 39(6):565-575.
View in: PubMed

Genome instability in multiple myeloma. Leukemia. 2020 11; 34(11):2887-2897.
View in: PubMed

Pro-organic radical contrast agents ("pro-ORCAs") for real-time MRI of pro-drug activation in biological systems. Polym Chem. 2020 Aug 07; 11(29):4768-4779.
View in: PubMed

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in: PubMed

Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. Cancers (Basel). 2020 Jun 12; 12(6).
View in: PubMed

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
View in: PubMed

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915.
View in: PubMed

The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. Cancer Epidemiol Biomarkers Prev. 2020 07; 29(7):1283-1289.
View in: PubMed

Intensification and consolidation therapy in multiple myeloma in the current era. Lancet Haematol. 2020 06; 7(6):e427-e429.
View in: PubMed

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020 May; 1(5):493-506.
View in: PubMed

Clinical Controversies in the Management of Smoldering Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-6.
View in: PubMed

The microenvironment in myeloma. Curr Opin Oncol. 2020 03; 32(2):170-175.
View in: PubMed

Bone marrow niches in haematological malignancies. Nat Rev Cancer. 2020 05; 20(5):285-298.
View in: PubMed

Prediagnosis dietary pattern and survival in patients with multiple myeloma. Int J Cancer. 2020 10 01; 147(7):1823-1830.
View in: PubMed

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
View in: PubMed

Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020 02 17; 10(2):19.
View in: PubMed

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. 2019 Nov; 30(11):1845.
View in: PubMed

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. 2019 11 01; 30(11):1845.
View in: PubMed

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clin Cancer Res. 2020 01 15; 26(2):344-353.
View in: PubMed

Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. Nanoscale. 2019 Nov 21; 11(43):20485-20496.
View in: PubMed

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
View in: PubMed

Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702.
View in: PubMed

Fluorescence monitoring of rare circulating tumor cell and cluster dissemination in a multiple myeloma xenograft model in vivo. J Biomed Opt. 2019 08; 24(8):1-11.
View in: PubMed

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 Aug 01; 25(15):4860.
View in: PubMed

Author Correction: Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 Jul; 15(7):757.
View in: PubMed

Immunotherapy for hematological malignancies. J Life Sci (Westlake Village). 2019 Jun; 1(1):46-52.
View in: PubMed

A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clin Cancer Res. 2019 08 15; 25(16):4907-4916.
View in: PubMed

Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 07; 15(7):681-689.
View in: PubMed

Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies. JNCI Cancer Spectr. 2019 Jun; 3(2):pkz025.
View in: PubMed

Monoclonal gammopathy of undetermined significance. Blood. 2019 06 06; 133(23):2484-2494.
View in: PubMed

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
View in: PubMed

Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019 04 09; 3(7):995-1002.
View in: PubMed

Kidney micro-organoids in suspension culture as a scalable source of human pluripotent stem cell-derived kidney cells. Development. 2019 03 07; 146(5).
View in: PubMed

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149.
View in: PubMed

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):332-344.
View in: PubMed

3D organoid-derived human glomeruli for personalised podocyte disease modelling and drug screening. Nat Commun. 2018 12 04; 9(1):5167.
View in: PubMed

Autologous graft versus myeloma: it's not a myth. J Clin Invest. 2019 01 02; 129(1):48-50.
View in: PubMed

Triply Loaded Nitroxide Brush-Arm Star Polymers Enable Metal-Free Millimetric Tumor Detection by Magnetic Resonance Imaging. ACS Nano. 2018 11 27; 12(11):11343-11354.
View in: PubMed

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
View in: PubMed

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018; 13(10):e0204589.
View in: PubMed

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486.
View in: PubMed

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia. 2019 01; 33(1):266-270.
View in: PubMed

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia. 2018 08; 32(8):1739-1750.
View in: PubMed

Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Adv. 2018 06 12; 2(11):1272-1276.
View in: PubMed

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018 06 01; 128(6):2487-2499.
View in: PubMed

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
View in: PubMed

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018 04 27; 9(1):1691.
View in: PubMed

Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):447-459.
View in: PubMed

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. . 2018 07; 17(7):1454-1463.
View in: PubMed

Targeting MYC in multiple myeloma. Leukemia. 2018 06; 32(6):1295-1306.
View in: PubMed

Platelets Enhance Multiple Myeloma Progression via IL-1ß Upregulation. Clin Cancer Res. 2018 05 15; 24(10):2430-2439.
View in: PubMed

The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018 04; 15(4):219-233.
View in: PubMed

Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. JCI Insight. 2017 11 02; 2(21).
View in: PubMed

Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. Endocrinology. 2017 10 01; 158(10):3369-3385.
View in: PubMed

Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. Curr Osteoporos Rep. 2017 10; 15(5):499-506.
View in: PubMed

A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. Am J Hematol. 2017 Aug; 92(8):E138-E145.
View in: PubMed

IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751.
View in: PubMed

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. Oncotarget. 2017 May 23; 8(21):35435-35444.
View in: PubMed

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017 06 29; 129(26):3452-3464.
View in: PubMed

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Sci Transl Med. 2017 05 10; 9(389).
View in: PubMed

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
View in: PubMed

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224.
View in: PubMed

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia. 2017 11; 31(11):2426-2434.
View in: PubMed

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017 May; 92(5):448-453.
View in: PubMed

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. 2017 03 01; 28(3):468-477.
View in: PubMed

Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017 04 27; 129(17):2429-2436.
View in: PubMed

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
View in: PubMed

Established and Novel Prognostic Biomarkers in Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2017; 37:548-560.
View in: PubMed

Multiple Myeloma and the Immune Microenvironment. Curr Cancer Drug Targets. 2017; 17(9):806-818.
View in: PubMed

Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A. 2016 12 27; 113(52):E8425-E8432.
View in: PubMed

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
View in: PubMed

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia. 2017 04; 31(4):853-860.
View in: PubMed

Epigenomics in Waldenstrom's macroglobulinaemia. Best Pract Res Clin Haematol. 2016 06; 29(2):156-160.
View in: PubMed

Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017 02; 14(2):100-113.
View in: PubMed

Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Curr Opin Hematol. 2016 07; 23(4):426-33.
View in: PubMed

Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 11; 51(11):1504-1506.
View in: PubMed

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am J Hematol. 2016 Jun; 91(4):400-5.
View in: PubMed

The Use of Silk as a Scaffold for Mature, Sustainable Unilocular Adipose 3D Tissue Engineered Systems. Adv Healthc Mater. 2016 07; 5(13):1667-77.
View in: PubMed

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
View in: PubMed

Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701.
View in: PubMed

Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606.
View in: PubMed

Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia. 2016 05; 30(5):1103-15.
View in: PubMed

Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. Cancer Res. 2016 Jan 15; 76(2):463-71.
View in: PubMed

Exosomes in Tumor Angiogenesis. Methods Mol Biol. 2016; 1464:25-34.
View in: PubMed

Epigenetics in Multiple Myeloma. Cancer Treat Res. 2016; 169:35-49.
View in: PubMed

Genomic Aberrations in Multiple Myeloma. Cancer Treat Res. 2016; 169:23-34.
View in: PubMed

Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. Am Soc Clin Oncol Educ Book. 2016; 35:e400-6.
View in: PubMed

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
View in: PubMed

Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Lett. 2016 09 28; 380(1):315-8.
View in: PubMed

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics. Ann Oncol. 2016 Feb; 27(2):233-40.
View in: PubMed

Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. J Mol Diagn. 2015 Nov; 17(6):669-78.
View in: PubMed

Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. Oncologist. 2015 Sep; 20(9):1077-83.
View in: PubMed

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 2015 Jul 28; 12(4):622-35.
View in: PubMed

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46.
View in: PubMed

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
View in: PubMed

Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4:27066.
View in: PubMed

Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
View in: PubMed

The road to cure in multiple myeloma starts with smoldering disease. Expert Opin Orphan Drugs. 2015 Apr 12; 3(6).
View in: PubMed

Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
View in: PubMed

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
View in: PubMed

American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma. Expert Rev Hematol. 2015 Jun; 8(3):273-5.
View in: PubMed

Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015 May 15; 75(10):2071-82.
View in: PubMed

Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone. 2015 Jun; 75:161-9.
View in: PubMed

The cancer glycome: carbohydrates as mediators of metastasis. Blood Rev. 2015 Jul; 29(4):269-79.
View in: PubMed

Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
View in: PubMed

Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015 Jan; 263(1):160-72.
View in: PubMed

Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
View in: PubMed

Global epigenetic regulation of microRNAs in multiple myeloma. PLoS One. 2014; 9(10):e110973.
View in: PubMed

How I treat smoldering multiple myeloma. Blood. 2014 Nov 27; 124(23):3380-8.
View in: PubMed

Team work matters: dual inhibition puts non-hodgkin lymphoma under siege. Clin Cancer Res. 2014 Dec 01; 20(23):5863-5.
View in: PubMed

SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep. 2014 Oct 09; 9(1):118-128.
View in: PubMed

Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia. Mol Cancer Res. 2015 Feb; 13(2):263-72.
View in: PubMed

Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014 Oct 23; 124(17):2675-86.
View in: PubMed

Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood. 2014 Nov 20; 124(22):3250-9.
View in: PubMed

Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. Am J Hematol. 2014 Nov; 89(11):1030-6.
View in: PubMed

The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood. 2014 Sep 11; 124(11):1765-76.
View in: PubMed

Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. Cytokine. 2014 Oct; 69(2):294-7.
View in: PubMed

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11.
View in: PubMed

Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A. 2014 Jul 15; 111(28):10287-92.
View in: PubMed

Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma. Palliat Support Care. 2015 Aug; 13(4):829-38.
View in: PubMed

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
View in: PubMed

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
View in: PubMed

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
View in: PubMed

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. Blood Cancer J. 2014 Apr 25; 4:e204.
View in: PubMed

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014 Jun 26; 123(26):4120-31.
View in: PubMed

Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta. 2014 Aug; 1846(1):26-39.
View in: PubMed

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014 Mar 24; 13:71.
View in: PubMed

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014 Mar; 89(3):237-42.
View in: PubMed

Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014 Apr; 1845(2):255-65.
View in: PubMed

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
View in: PubMed

Waldenström macroglobulinemia: from biology to treatment. Expert Rev Hematol. 2014 Feb; 7(1):157-68.
View in: PubMed

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Curr Cancer Ther Rev. 2014; 10(2):70-79.
View in: PubMed

microRNA aberrations and their role in supporting hematologic malignancies. Microrna. 2014; 2(3):157.
View in: PubMed

The role of miRNAs in plasma cell dyscrasias. Microrna. 2014; 2(3):165-73.
View in: PubMed

Novel treatment options for Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S310-6.
View in: PubMed

Candidate genes of Waldenström's macroglobulinemia: current evidence and research. Appl Clin Genet. 2013; 6:33-42.
View in: PubMed

Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. PLoS One. 2013; 8(6):e66982.
View in: PubMed

Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new? Leuk Lymphoma. 2013 Oct; 54(10):2328-30.
View in: PubMed

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan; 28(1):155-65.
View in: PubMed

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013 Apr; 123(4):1542-55.
View in: PubMed

Update on Waldenström's macroglobulinemia. Clin Adv Hematol Oncol. 2013 Apr; 11(4):244-6.
View in: PubMed

The bone marrow microenvironment in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):218-21.
View in: PubMed

microRNA aberrations in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):205-7.
View in: PubMed

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013 Feb 21; 121(8):1296-303.
View in: PubMed

Extramedullary multiple myeloma. Leuk Lymphoma. 2013 Jun; 54(6):1135-41.
View in: PubMed

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
View in: PubMed

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
View in: PubMed

Choice of therapy for patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2013 Jan 20; 31(3):291-3.
View in: PubMed

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res. 2013 Mar 01; 19(5):985-94.
View in: PubMed

The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression. Leukemia. 2013 Apr; 27(4):961-4.
View in: PubMed

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6.
View in: PubMed

Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. Clin Cancer Res. 2012 Dec 15; 18(24):6609-22.
View in: PubMed

Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012; 2012:157496.
View in: PubMed

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer. 2012 Sep; 15(3):273-82.
View in: PubMed

Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma. 2013 Feb; 54(2):229-41.
View in: PubMed

A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res. 2012 Sep 15; 18(18):5043-50.
View in: PubMed

LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1678-86.
View in: PubMed

Would the real myeloma cell please stand up? Leuk Lymphoma. 2012 Oct; 53(10):1851-2.
View in: PubMed

Multimodality imaging in amyloidosis. Cancer Imaging. 2012 Apr 27; 12:109-17.
View in: PubMed

Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012 Jul 05; 120(1):20-30.
View in: PubMed

Does my patient with a serum monoclonal spike have multiple myeloma? Hematol Oncol Clin North Am. 2012 Apr; 26(2):383-93, ix.
View in: PubMed

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
View in: PubMed

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012 Jun 14; 119(24):5782-94.
View in: PubMed

Cell Trafficking in Multiple Myeloma. Open J Hematol. 2012 Feb 21; 3(Suppl 1).
View in: PubMed

Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
View in: PubMed

Are you sure this is Waldenstrom macroglobulinemia? Hematology Am Soc Hematol Educ Program. 2012; 2012:586-94.
View in: PubMed

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012 May; 26(5):985-90.
View in: PubMed

Serum galactomannan and (1->3)-ß-D-glucan assays for patients with multiple myeloma and Waldenstrom's macroglobulinemia. J Clin Microbiol. 2012 Mar; 50(3):1054-6.
View in: PubMed

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
View in: PubMed

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012 Feb 09; 119(6):1468-78.
View in: PubMed

Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2012 Jan 15; 18(2):342-9.
View in: PubMed

Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia. Curr Cancer Drug Targets. 2011 Nov; 11(9):1025-9.
View in: PubMed

Defining the role of TORC1/2 in multiple myeloma. Blood. 2011 Dec 22; 118(26):6860-70.
View in: PubMed

Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. Clin Cancer Res. 2012 Jan 01; 18(1):91-104.
View in: PubMed

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
View in: PubMed

Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
View in: PubMed

BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
View in: PubMed

The bone marrow microenvironment in waldenstrom macroglobulinemia. Ther Adv Hematol. 2011 Aug; 2(4):267-72.
View in: PubMed

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
View in: PubMed

The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011 Jul; 86(7):567-72.
View in: PubMed

New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol. 2011 Jul; 18(4):260-5.
View in: PubMed

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
View in: PubMed

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
View in: PubMed

Targeting the bone marrow in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S65-9.
View in: PubMed

FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res. 2011 Jul 01; 17(13):4389-99.
View in: PubMed

Integrin ß7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 2011 Jun 09; 117(23):6202-13.
View in: PubMed

The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. Clin Cancer Res. 2011 May 01; 17(9):3013-8.
View in: PubMed

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar; 11(3):254-84.
View in: PubMed

Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res. 2011 Apr 01; 17(7):1753-64.
View in: PubMed

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
View in: PubMed

Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):109-11.
View in: PubMed

Novel M-component based biomarkers in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):164-7.
View in: PubMed

The bone marrow niche in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):118-20.
View in: PubMed

Novel agents in Waldenström macroglobulinemia. Clin Investig (Lond). 2011; 1(6):815-824.
View in: PubMed

Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt. 2011 Jan-Feb; 16(1):011006.
View in: PubMed

Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Semin Hematol. 2011 Jan; 48(1):39-45.
View in: PubMed

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb; 25(2):341-7.
View in: PubMed

An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma. Am J Hematol. 2010 Dec; 85(12):944-6.
View in: PubMed

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget. 2010 Nov; 1(7):578-82.
View in: PubMed

Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol. 2010 Oct 07; 3:38.
View in: PubMed

Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010 Oct; 51(10):1779-92.
View in: PubMed

Epigenetics in Waldenström's macroglobulinemia. Epigenomics. 2010 Oct; 2(5):691-6.
View in: PubMed

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4.
View in: PubMed

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
View in: PubMed

microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood. 2010 Sep 02; 116(9):1506-14.
View in: PubMed

Novel agents in Waldenstrom Macroglobulinemia. Open J Hematol. 2010 May 28; 1.
View in: PubMed

The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
View in: PubMed

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
View in: PubMed

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
View in: PubMed

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
View in: PubMed

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8.
View in: PubMed

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
View in: PubMed

Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
View in: PubMed

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 2010 May 20; 115(20):4051-60.
View in: PubMed

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 01; 16(3):1033-41.
View in: PubMed

New Therapeutic Approaches for Waldenstrom Macroglobulinemia. Drugs Future. 2010 Jan; 35(1):53-58.
View in: PubMed

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. 2010 Jan 21; 115(3):559-69.
View in: PubMed

Individualizing treatment for Waldenstrom's macroglobulinemia. Expert Rev Hematol. 2009 Oct; 2(5):473-6.
View in: PubMed

Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
View in: PubMed

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
View in: PubMed

Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res. 2009 Oct 01; 15(19):6035-41.
View in: PubMed

The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
View in: PubMed

Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
View in: PubMed

Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics. 2009; 3:99-109.
View in: PubMed

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10; 27(23):3830-5.
View in: PubMed

Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):8535.
View in: PubMed

Diagnostic and prognostic use of FDG-PET scans in Waldenstrom's macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):e19518.
View in: PubMed

MicroRNAs 15a and 16-1 regulates tumor proliferation in multiple myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):e14640.
View in: PubMed

Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. J Clin Oncol. 2009 May 20; 27(15_suppl):8536.
View in: PubMed

Role of selectins in the pathogenesis of multiple myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):11103.
View in: PubMed

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009 Jul 16; 114(3):619-29.
View in: PubMed

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
View in: PubMed

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009 Jun 25; 113(26):6669-80.
View in: PubMed

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009 Apr 15; 69(8):3579-88.
View in: PubMed

Bortezomib and Waldenstrom's macroglobulinemia. Expert Opin Pharmacother. 2009 Apr; 10(5):909-16.
View in: PubMed

Novel therapeutic agents in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):84-6.
View in: PubMed

High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma. 2009 Mar; 9(1):39-42.
View in: PubMed

Role of proteasome inhibition in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):94-6.
View in: PubMed

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar; 9(1):71-3.
View in: PubMed

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr; 145(1):59-63.
View in: PubMed

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51.
View in: PubMed

Multiple myeloma: biology, standard therapy, and transplant therapy. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):46-52.
View in: PubMed

Finding the right academic job. Hematology Am Soc Hematol Educ Program. 2009; 729-33.
View in: PubMed

Update on therapeutic options in Waldenström macroglobulinemia. Eur J Haematol. 2009 Jan; 82(1):1-12.
View in: PubMed

ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? Hematology Am Soc Hematol Educ Program. 2009; 587-9.
View in: PubMed

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood. 2009 Apr 30; 113(18):4391-402.
View in: PubMed

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10; 27(2):250-5.
View in: PubMed

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 Jan 01; 27(1):120-6.
View in: PubMed

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15; 113(3):626-34.
View in: PubMed

Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma. 2008 Sep; 49(9):1738-44.
View in: PubMed

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
View in: PubMed

The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.
View in: PubMed

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008 Aug 01; 113(3):508-14.
View in: PubMed

Proteomics analysis in post-transplant lymphoproliferative disorders. Eur J Haematol. 2008 Oct; 81(4):298-303.
View in: PubMed

Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
View in: PubMed

Waldenstrom macroglobulinemia. Cancer Lett. 2008 Oct 18; 270(1):95-107.
View in: PubMed

The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008 Sep; 142(5):775-85.
View in: PubMed

Targeted therapies in Waldenström macroglobulinemia. Curr Opin Investig Drugs. 2008 Jun; 9(6):631-7.
View in: PubMed

Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008 Jun; 49(6):1104-7.
View in: PubMed

Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). J Clin Oncol. 2008 May 20; 26(15_suppl):8546.
View in: PubMed

Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study. J Clin Oncol. 2008 May 20; 26(15_suppl):8520.
View in: PubMed

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood. 2008 Jul 01; 112(1):150-8.
View in: PubMed

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008 Mar 15; 14(6):1849-58.
View in: PubMed

Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008 May 15; 111(10):5068-77.
View in: PubMed

Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. Eur J Haematol. 2008 Jun; 80(6):503-9.
View in: PubMed

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 01; 111(9):4752-63.
View in: PubMed

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
View in: PubMed

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007 Dec 15; 110(13):4417-26.
View in: PubMed

Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.
View in: PubMed

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007 Jul 01; 13(13):3771-5.
View in: PubMed

Novel Therapeutic Avenues in Myeloma: Changing the Paradigm. Oncology. 2007.

Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park). 2007 Jun; 21(7):785-92; discussion 798-800.
View in: PubMed

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63.
View in: PubMed

Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67(8):3777-84.
View in: PubMed

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007 Apr 01; 109(7):2708-17.
View in: PubMed

Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007 Mar; 12(1):155-63.
View in: PubMed

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007 Jun 01; 109(11):4964-72.
View in: PubMed

Novel treatments in multiple myeloma. Hospital Pharmacy Europe. 2007; 81-83.

The PI3k/Akt pathway is an important regulator of homing and adhesion in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.

Update on novel therapeutic agents in Waldenstom Macroglobulinemia. Translational Therapeutic Strategies in Multiple Myeloma. 2007.

A selective protein kinase C inhibitor Enzastaurin, induces in vitro and in vivo cytotoxicity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.

A novel real-time in vivo homing model of multiple myeloma. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007 Jan; 82(1):83-4.
View in: PubMed

Non-Hodgkin Lymphoma. William's Hematology. 2007.

Novel Agent Perifosine enhances antitumor activity of Bortezomib and rituximab in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.

The Proteasome inhibitor NPI-0052 incombination with bortezomib induces antitumor activity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.

Perifosine, an oral bioactive AKT inhibitor induces in vitro and in vivo antitumor activity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.

The combination of the mTOR inhibitor rapamycin and proteasome inhibitor Bortezomib is synergistic in vitro in Multiple Myeloma. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.

The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
View in: PubMed

Targeting Akt and HSP90 produces synergistic Multiple Myeloma cell cytoxicity in the bone marrow microenvironment. Blood. 2007.

The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenstrom macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.

Targeting the PI3K pathway in Multiple Myeloma. Clinical Cancer Research. 2007.

New frontiers in the treatment of multiple myeloma. ScientificWorldJournal. 2006 Dec 06; 6:1475-503.
View in: PubMed

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res. 2006 Nov 15; 12(22):6826-35.
View in: PubMed

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
View in: PubMed

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007 Apr 05; 26(16):2374-80.
View in: PubMed

Chemokines in multiple myeloma. Exp Hematol. 2006 Oct; 34(10):1289-95.
View in: PubMed

The emerging role of novel therpeutic agents int he management of patients with multiple myeloma. Community Oncology. 2006; 3(9):575-582.

6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006 Sep; 169(2):150-3.
View in: PubMed

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006 Oct 15; 108(8):2755-63.
View in: PubMed

Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7556.
View in: PubMed

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006 Apr; 133(2):158-64.
View in: PubMed

The PI3K/Akt pathway is an important regulator of homing and adhesion in Waldenstrom Macroglobulinemia. ASH. 2006.

A selection protein kinase C inhibitor Enzastaurin, induces in vitro and in vivo cytotoxicity in Waldenstrom Macroglobulinemia. ASH. 2006.

The Proteasome inhibitor NPI-0052 incombination with bortezomib induces antitumor activity in Waldenstrom Macroglobulinemia. ASH. 2006.

The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenstrom Macroglobulinemia. ASH. 2006.

Novel Agent Perifosine enhances antitumor activity of Bortezomib and rituximab in Waldenstrom Macroglobulinemia. ASH. 2006.

A novel real-time in vivo homing model of multiple myeloma. ASH. 2006.

The combination of the mTOR inhibitor rapamycin and proteasome inhibitor Bortezomib in synergistic in vitro in Multiple Myeloma. ASH. 2006.

Perifosine, an oral bioactive AKT inhibitor induces in vitro and in vivo antitumor activity in Waldenstroms Macroglobulinemia. ASH. 2006.

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006 Apr 15; 107(8):3098-105.
View in: PubMed

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005 Oct 20; 23(30):7574-82.
View in: PubMed

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005 Aug 10; 23(23):5347-56.
View in: PubMed

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005 Aug 15; 106(4):1407-14.
View in: PubMed

Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2005 May; 46(5):703-8.
View in: PubMed

Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005 May-Jun; 55(3):178-94.
View in: PubMed

Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays. Cancer Res. 2005 Apr 15; 65(8):2985-9.
View in: PubMed

Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005 Feb; 46(2):191-6.
View in: PubMed

Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005 Jan 27; 79(2):244-7.
View in: PubMed

Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood. 2005 May 01; 105(9):3722-30.
View in: PubMed

Role of the CXCR4 inhibitor AMD3100 in mulitple myeloma (MM). ASH. 2005.

Zoledronic acid inhibits CXCR-4-mediated prostate cancer cell invasion through an NFɻB independent pathway in vitro. AACR. 2005.

Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. 10Th International Myeloma Workshop. 2005.

Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4 Stimulation and Downstream Activation of The PI3K Pathway. 10Th International Myeloma Workshop. 2005.

The effect of rapamycin, 17-AAG and the combination on the bone marrow microenvironment in Multiple Myeloma (MM). ASH. 2005.

Proteomic analysis identifies differences in multiple myeloma (MM) cells sensitive and resistant to AKT inhibition. ASH. 2005.

The Role of CXCR4 inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. 10th Annyal Internation Myeloma Workshop. 2005.

Differential response to proteosome inhibition in EBV positive and negative lymphoma cell lines: clinical implications in post transplant lymphoproliferative disorders (PtLD). 2005.

Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. 10th Annual Myeloma Workshop. 2005.

Role of cathepsin K in prostate cancer skeletal metastasis. AACR. 2005.

Combination of the AKT inhibitor perifosine with the HSP90 inhibitor 17-(dimethylaminoethyulamino)-17-demethoxygeldanamycin (17-DMAG) has synergistic activity in Multiple Myeloma (MM). ASH. 2005.

Zoledronic acid inhibits CXCR-4 mediated prostate cancer cell invasion through an NFE>>B independent pathway in vitro. AACR. 2005.

Combination of the mTOR inhibitor rapamycin with the HSP90 inhibitor 17-AAG has synergistic activity in EBV positive and negative post transplant lymphoproliferative disorders (PTLD). ASH. 2005.

Proteomic analysis of Waldenstrom Macroglobulinemia (WM) using nanoscale protein microarray techniques. ASH. 2005.

Role of cathepsin K in prostate cancer skeletal meastasis. AACR. 2005.

The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. 10Th International Myeloma Workshop. 2005.

The role of the AKT inhibitor perifosine in migration and adhesion in multiple myeloma (MM). ASH. 2005.

Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). 10th International Myeloma Workshop. 2005.

Role of the chemokine receptor CXCR4 in Waldenstrom Macroglobulinemia. ASH. 2005.

Molecular mechanisms regulating migration and adhesion in response to the chemokine SDF-1 in multiple myeloma (MM). ASH. 2005.

Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17AAG in Multiple Myeloma. ASCO. 2005.

Proteomic analysis of post transplant lymphoproliferative disorders (PTLD) using nanoscale protein microarray techniques. ASH. 2005.

Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 01; 101(11):2593-8.
View in: PubMed

Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Am J Hematol. 2004 Dec; 77(4):329-30.
View in: PubMed

Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6530.
View in: PubMed

Waldenström macroglobulinemia. Curr Treat Options Oncol. 2004 Jun; 5(3):239-47.
View in: PubMed

High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. Cancer. 2004 Jun 01; 100(11):2403-7.
View in: PubMed

Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology (Williston Park). 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640.
View in: PubMed

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin Proc. 2004 Mar; 79(3):318-25.
View in: PubMed

Fatal coronary artery disease after unrelated donor bone marrow transplantation. Mayo Clin Proc. 2004 Mar; 79(3):403-6.
View in: PubMed

Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc. 2004 Feb; 79(2):169-75.
View in: PubMed

Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. ASH . 2004.

Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway. ASH. 2004.

Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy. ASH. 2004.

The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. ASH. 2004.

Experimental Design & Analysis of Protein Array Data: Applying Methods from cDNA Arrays. ASH. 2004.

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. National Institute of Health. 2004.

Proteomic analysis of mantle cell lymphoma. National Institute of Health. 2004.

Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90 and other proteins as potential target(s) for drug therapy. ASCO. 2004.

Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy . ASH. 2004.

Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). ASH. 2004.

Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4 Stimulation and Downstream Activation of The PI3K Pathway. ASH. 2004.

Characterization of Waldenström Macroglobulinemia Subtypes Using Global Gene Expression Profiling. ASH. 2004.

CCI-779 inhibits phosphorylation of ribosomal S6 (pS6) in mantle cell lymphoma. AACR. 2004.

Renal cell carcinoma with acrometastasis and scalp metastasis. Mayo Clin Proc. 2004 Jan; 79(1):76.
View in: PubMed

An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med. 2003 Dec 25; 349(26):2570-2; discussion 2570-2.
View in: PubMed

Waldenström macroglobulinaemia. Lancet Oncol. 2003 Nov; 4(11):679-85.
View in: PubMed

Management of thalidomide toxicity. J Support Oncol. 2003 Sep-Oct; 1(3):194-205.
View in: PubMed

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant. 2003 Sep; 32(6):587-92.
View in: PubMed

Rituximab and IPI are prognostic indicators in post transplant lymphoproliferative disorders (PTLD). American Society of Clinical Oncology. 2003.

Prognostic model for patients with Post Transplant Lymphoproliferative Disorders. Blood. 2003.

The IgM flare in patients diagnosed with Waldenstrom Macroglobulinemia and treated with rituximab: an ECOG study. Blood. 2003.

CNS Post Transplant Lymphoproliferative Disorders: therapy with rituximab. Blood. 2003.

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Panpacific Lymphoma Conference. 2003.

Differences between early and late Post Transplant Lymphoproliferative Disorders: are they two different diseases. Blood. 2003.

Prognostic model for 506 patients diagnosed with Waldenstrom Macroglobulinemia,. Blood. 2003.

Therapeutic options in patients with lymphoma and severe liver dysfunction. Blood. 2003.

Deletions of 6q predominantly involve band q23 and distinguish Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Blood. 2003.

Subcutaneous Panniculitis-like T cell lymphoma: clinical presentation and follow up of 17 patients. Blood. 2003.

Inhibitors of the ras oncogene as therapeutic targets. Hematol Oncol Clin North Am. 2002 Oct; 16(5):1065-88.
View in: PubMed

T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Transplant Proc. 1991 Feb; 23(1 Pt 1):81-2.
View in: PubMed

The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging. Transplantation. 1990 Oct; 50(4):683-9.
View in: PubMed

T cells in patients undergoing chronic hemodialysis: mitogenic response, suppressor activity, and interleukin-2 production and receptor generation. Diagn Immunol. 1986; 4(4):209-16.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Harvard Institute of Medicine 240
Boston, MA 02215
Get Directions

Ratings

Top